news

65 Startups Named to MedTech Innovator 2024 Cohort

The American Urological Association (AUA) and Society for Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) recently published their 2024 Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder (OAB).  The guideline promotes a shared decision-making process between the patient and physician that weighs the patient’s comorbidities along with expressed values, preferences, and treatment […]

We are looking forward to presenting the Neuspera Medical journey update at the Jefferies Global Healthcare Conference in New York early June 2024.    

The international study is evaluating the safety and efficacy of the Neuspera System for the treatment of urinary urge incontinence (UUI), a symptom of overactive bladder (OAB) SAN JOSE, Calif., Dec. 6, 2023 /PRNewswire/ — Neuspera Medical, Inc., a neuromodulation company pioneering the Neuspera Implantable Sacral Neuromodulation (SNM) System, today announced it has completed patient enrollment and implant procedures […]

The nationwide study is evaluating the safety and efficacy of the Neuspera System for the treatment of urinary urge incontinence (UUI), a symptom of overactive bladder (OAB) SAN JOSE, Calif. , Nov. 14, 2023 /PRNewswire/ — Neuspera Medical, Inc., a neuromodulation company pioneering the Neuspera Implantable Sacral Neuromodulation (SNM) System, today announced the completion of the 100th implant of its Neuspera […]

First-of-its-kind, leadless micro-implant for chronic peripheral nerve pain management SAN JOSE, Calif., April 18, 2023 /PRNewswire/ — Neuspera® Medical, a medical device company developing implantable devices for patients battling chronic illnesses, today announced it received U.S. Food and Drug Administration (FDA) clearance for the next-generation Neuspera ultra-miniaturized system. The system is comprised of a micro-implant that delivers neurostimulation […]

SAN JOSE, CA – February 1, 2023 — Neuspera® Medical, a medical device company developing miniaturized neuromodulation technology for patients with chronic illnesses, announces the hiring of Courtney Lane as Vice President, Clinical and Regulatory Affairs. The fast-growing early-stage company is progressing through enrollment of the second stage of its pivotal study (SANS-UUI) to evaluate […]

Study to support U.S. FDA approval of sacral neuromodulation device in patients with urinary urgency incontinence symptoms SAN JOSE, Calif., Oct. 10, 2022 /PRNewswire/ — Neuspera® Medical, a medical device company developing implantable devices for patients battling chronic illnesses, today announced the first patient successfully implanted with the Nuvella™ system in its pivotal clinical trial (SANS-UUI). The […]

Hovard brings a wealth of medical device senior leadership experience to the company as it works to advance sacral neuromodulation therapies   SAN JOSE, Calif., Sept. 6, 2022 /PRNewswire/ — Neuspera® Medical, a medical device company developing implantable medical device technology for patients with chronic illness, today announced the hiring of seasoned medtech executive, Steffen Hovard as Chief Executive Officer. […]

San Jose, CA – August 4, 2022– Neuspera® Medical, a medical device company developing implantable medical device technology for patients battling chronic illness, today announced the hiring of Steven Siegel, MD, as Chief Medical Officer. Dr. Siegel joined Neuspera as the company recently began enrollment of the second phase of their pivotal clinical trial (SANS-UUI). […]